IOVA Iovance Biotherapeutics Inc

Price (delayed)

$7.55

Market cap

$3.49B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.5

Enterprise value

$3.47B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 29

Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to ...

Highlights
The gross profit has soared by 144% YoY and by 28% from the previous quarter
The company's gross margin has surged by 61% YoY and by 10% QoQ

Key stats

What are the main financial stats of IOVA

IOVA stock price

How has the Iovance Biotherapeutics stock price performed over time
Intraday
-2.71%
1 week
-7.59%
1 month
-44.57%
1 year
205.67%
YTD
176.56%
QTD
-49.06%

Financial performance

How have Iovance Biotherapeutics's revenue and profit performed over time
Revenue
$378.98M
Gross profit
$201.75M
Operating income
-$230.38M
Net income
-$220.54M
Gross margin
53.2%
Net margin
-58.2%
The gross profit has soared by 144% YoY and by 28% from the previous quarter
Iovance Biotherapeutics's net margin has soared by 63% YoY and by 35% from the previous quarter
The operating margin has soared by 63% YoY and by 34% from the previous quarter
The company's gross margin has surged by 61% YoY and by 10% QoQ

Price vs fundamentals

How does IOVA's price correlate with its fundamentals

Growth

What is Iovance Biotherapeutics's growth rate over time

Valuation

What is Iovance Biotherapeutics stock price valuation
P/E
N/A
P/B
4.21
P/S
9.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.17
The EPS has soared by 58% YoY and by 29% from the previous quarter
IOVA's price to book (P/B) is 36% more than its 5-year quarterly average of 3.1 and 17% more than its last 4 quarters average of 3.6
IOVA's equity is up by 16% year-on-year and by 10% since the previous quarter
IOVA's revenue has soared by 51% YoY and by 17% QoQ
The price to sales (P/S) is 12% higher than the last 4 quarters average of 8.1

Efficiency

How efficient is Iovance Biotherapeutics business performance
The ROS has soared by 63% YoY and by 35% from the previous quarter
Iovance Biotherapeutics's ROIC has increased by 50% YoY and by 34% from the previous quarter
The ROE is up by 46% year-on-year and by 27% since the previous quarter
The return on assets has increased by 45% year-on-year and by 25% since the previous quarter

Dividends

What is IOVA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IOVA.

Financial health

How did Iovance Biotherapeutics financials performed over time
The company's quick ratio has surged by 56% YoY and by 22% QoQ
The current ratio has soared by 52% YoY and by 20% from the previous quarter
Iovance Biotherapeutics's debt is 94% less than its equity
IOVA's equity is up by 16% year-on-year and by 10% since the previous quarter
Iovance Biotherapeutics's debt has decreased by 14% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.